A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Sponsor: Erasca, Inc.
This PHASE1 trial investigates Glioblastoma Multiforme and is currently ongoing. Erasca, Inc. leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Nov 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Dec 2022 — Nov 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
First recorded
Feb 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasca, Inc.
- Katmai Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .